Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SALL4 | Q9UJQ4 | 9/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 8/20 | 0.33 |
| ▸ | GSPT1 | P15170 | 7/20 | 0.33 |
| ▸ | IKZF3 | Q9UKT9 | 7/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6042700 | 0.67 | CHRM2 (0.39) | SALL4CSNK1A1 | |
| SCHEMBL6042380 | 0.67 | CHRM2 (0.35) | SALL4CSNK1A1 | |
| SCHEMBL6042866 | 0.65 | OPRK1 (0.45) | — | |
| SCHEMBL27654446 | 0.61 | KMT2A (0.45) | — | |
| SCHEMBL1427539 | 0.60 | CA12 (0.57) | — | |
| SCHEMBL3585852 | 0.59 | HSD11B1 (0.45) | NPSR1LMNA | |
| SCHEMBL27674461 | 0.59 | ESR1 (0.46) | — | |
| SCHEMBL4662764 | 0.59 | CA12 (0.43) | — | |
| SCHEMBL21855146 | 0.59 | CA12 (0.43) | LMNA | |
| SCHEMBL3633446 | 0.58 | CA12 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | NPSR1 249/4885SALL4 4166/4885CSNK1A1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.